News | November 03, 2009

PETNET to Supply ACRIN Multicenter Trial Network

18F-NaF PET image

November 2, 2009 - PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions, announced it is a registered supplier of 18F-sodium fluoride  (18F-NaF) and investigational 3’Deoxy-3’[18F] Fluorothymidine (18F-FLT)  to the American College of Radiology Imaging Network (ACRIN) in support of ACRIN’s multi-center clinical trials.
 
Availability of 18F-NaF and 18F-FLT will be made via a cross reference from Siemens’ Drug Master Files (DMF) to the National Cancer Institutes (NCI) centralized IND’s, under which the ACRIN trial will be performed.  The cross reference allows both products to be produced and used by any principle investigator in an ACRIN clinical trial. In addition, the imaging biomarkers will be available to investigators outside of ACRIN trials if they receive independent FDA approval of an IND or appropriate authorization, such as a local Radioactive Drug Research Committee (RDRC) approval or Institutional Review Board (IRB) approval.
 
18F-FLT has been used in studies to monitor the proliferative activity of cancer cells.  18F-sodium fluoride (18F-NaF) is an FDA-approved imaging agent and will be studied in the detection of bony metastases. Clinical trial support of both imaging agents provides the medical community with better access to 18F-FLT and 18F-NaF by leveraging Siemens biomarker technology and PETNET Solutions as the industry’s largest network of PET biomarker production facilities.
 
For more information: www.siemens.com/healthcare

Related Content

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...